4.83
-0.01 (-0.21%)
| Penutupan Terdahulu | 4.84 |
| Buka | 4.80 |
| Jumlah Dagangan | 1,715,725 |
| Purata Dagangan (3B) | 1,320,760 |
| Modal Pasaran | 514,849,024 |
| Harga / Buku (P/B) | 1.58 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 24 Mar 2025 - 28 Mar 2025 |
| EPS Cair (TTM) | -1.03 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 8.37% |
| Nisbah Semasa (MRQ) | 21.81 |
| Aliran Tunai Operasi (OCF TTM) | -101.74 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -60.81 M |
| Pulangan Atas Aset (ROA TTM) | -24.83% |
| Pulangan Atas Ekuiti (ROE TTM) | -42.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Annexon, Inc. | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -3.5 |
| Purata | -1.00 |
|
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 0.50% |
| % Dimiliki oleh Institusi | 106.10% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Logos Global Management Lp | 30 Sep 2024 | 2,600,000 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 30.00 (HC Wainwright & Co., 521.12%) | Beli |
| Median | 23.00 (376.19%) | |
| Rendah | 16.00 (Needham, 231.26%) | Beli |
| Purata | 23.00 (376.19%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 5.50 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 17 Dec 2024 | 30.00 (521.12%) | Beli | 4.88 |
| 15 Nov 2024 | 30.00 (521.12%) | Beli | 6.12 | |
| Needham | 15 Nov 2024 | 16.00 (231.26%) | Beli | 6.12 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |